Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01604772 · OUTCOME

Median Progression Free Survival

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma · Source last updated 2019-05-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Time of study entry to progression or death, up to 3 years after registration

What was measured

Progression Free Survival is defined as the time from registration to the earliest date of documentation of disease progression or death. The distribution of time to progression will be estimated using the method of Kaplan-Meier.

Analysis population: Two patients were deemed ineligible and were not included in this endpoint.

Groups in this outcome

Treatment (Akt Inhibitor MK2206)

Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Akt Inhibitor MK2206: 150 mg given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Akt Inhibitor MK2206)14

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Akt Inhibitor MK2206)9.7Not reported3.811.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3.8
        upper Limit
        11.8
        value
        9.7
denoms
  1. counts
    1. group Id
      OG000
      value
      14
    units
    Participants
description
Progression Free Survival is defined as the time from registration to the earliest date of documentation of disease progression or death. The distribution of time to progression will be estimated using the method of Kaplan-Meier.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Akt Inhibitor MK2206: 150 mg given PO
    id
    OG000
    title
    Treatment (Akt Inhibitor MK2206)
param Type
MEDIAN
population Description
Two patients were deemed ineligible and were not included in this endpoint.
reporting Status
POSTED
time Frame
Time of study entry to progression or death, up to 3 years after registration
title
Median Progression Free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice